American Journal of Tropical Medicine and Hygiene
Volume 102, Issue 1, 2020
Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6–17 Years
James M. McCarty, Emma C. Gierman, Lisa Bedell, Michael D. Lock and Sean Bennett
These data demonstrate that PXVX0200 may be a safe, tolerable cholera vaccine option that produces a robust vibriocidal antibody response in children and adolescents aged 6–17 years and would be expected to provide protection against cholera in this pediatric population from developed countries who are at an increased risk of infection when traveling to or residing in at-risk countries.